ImmunityBio
IBRX
278 hedge funds and large institutions have $338M invested in ImmunityBio in 2025 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 98 increasing their positions, 66 reducing their positions, and 28 closing their positions.
64% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 28
48% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 66
5% more funds holding
Funds holding: 264 → 278 (+14)
2.03% more ownership
Funds ownership: 15.14% → 17.17% (+2%)
4% less capital invested
Capital invested by funds: $352M → $338M (-$13.8M)
32% less call options, than puts
Call options by funds: $6.46M | Put options by funds: $9.55M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.1M |
| 2 |
State Street
Boston,
Massachusetts
|
+$11.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.6M |
| 4 |
Goldman Sachs
New York
|
+$11.4M |
| 5 |
Two Sigma Investments
New York
|
+$4.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Heights Capital Management
San Francisco,
California
|
-$16.2M |
| 2 |
Citigroup
New York
|
-$5.15M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$4.19M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.81M |
| 5 |
SPS
Susquehanna Portfolio Strategies
Bala Cynwyd,
Pennsylvania
|
-$968K |
IBRX Hedge Fund Activity: Q4 2025 in Review
278 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q4 2025, worth a combined $338M — down 3.9% from $352M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new IBRX positions and 28 closed out — a net gain of 18 holders — while 98 added to existing stakes and 66 trimmed.
The largest buyer was BlackRock, adding an estimated $13.1M. The largest seller was Heights Capital Management, exiting entirely with an estimated $16.2M sold.
- 278 institutional investors held ImmunityBio (IBRX) as of Q4 2025, up from 264 in Q3 2025.
- Funds reported $338M of ImmunityBio stock for Q4 2025, down 3.9% quarter-over-quarter.
- 46 funds opened new ImmunityBio positions in Q4 2025 and 28 closed out, a net change of +18 holders.
- The largest ImmunityBio buyer in Q4 2025 was BlackRock, an estimated $13.1M added.
- The largest ImmunityBio seller in Q4 2025 was Heights Capital Management, an estimated $16.2M sold.
Based on aggregated 13F filings for Q4 2025.